Elevidys (delandistrogene moxeparvovec) for a UAE family: what the pathway looks like in 2026
*Clinically reviewed by Mohammad Ali, MD (US-trained physician, Chief AI Officer, Reserve Meds). Last reviewed 2026-05-20.
A UAE family of a son with Duchenne muscular dystrophy walks into this decision with more than a treatment question. There is a clinical question, a regulatory question, a financial one, and a family one, and they all need answers in roughly the same week. This page is meant to be the first honest read you get on Elevidys in the UAE, from the people who would coordinate it for your son if you decided to go forward. We assume your paediatric neurologist has either raised it with you or you have raised it with them.
We will be specific about what changed in 2025 about who Elevidys is actually for, what the workup decides, what it costs in AED and US dollars, where the infusion can be given in the UAE, and what life looks like in the six months after.
What changed in June 2025, and why it matters before anything else
In June 2025, after two fatal acute liver failure events in non-ambulatory patients who had been treated with Elevidys, Sarepta voluntarily paused distribution for non-ambulatory boys. The US Food and Drug Administration then added a boxed warning, the strongest warning the FDA issues, and narrowed the approved indication. As of 2026, Elevidys is approved for ambulatory boys aged 4 and older with a genetically confirmed DMD mutation. Non-ambulatory patients are not currently treated outside of specific trial settings, and the same restriction is mirrored by the manufacturer's qualified-centre network internationally.
We mention this first because it determines whether the rest of this page is relevant to your son. If your son is still walking, even imperfectly, the door is open. If your son has lost ambulation, the candid answer is that the door is closed for now and we will help you think about what else is appropriate, including newer exon-skipping options for eligible mutations and the supportive-care pathway. A concierge that pretends otherwise is doing a family no favour.
The under-4 group is also outside the approved indication. We have had families ask about waiting. The answer your paediatric neurologist will give is that the window is age- and stage-sensitive. The benefit of the therapy is highest when there is still dystrophin-producing muscle mass to preserve. Time matters.
What Elevidys actually is, in plain terms
Elevidys is a single intravenous infusion. The active ingredient is an adeno-associated virus, type rh74, that has been engineered to carry a shortened version of the dystrophin gene called micro-dystrophin. Once infused, the virus delivers that gene to muscle cells, which begin producing a shorter, partially functional version of dystrophin protein. The native DMD gene is too large to package into the virus, which is why the therapy uses a shortened version designed by Sarepta in collaboration with the Nationwide Children's Hospital team that originated this approach.
What Elevidys is not is a cure. The clinical data describe a disease-modifying therapy: a slowing of functional decline against the natural history of DMD, with variability across patients. Your neurologist will walk you through the most recent functional data, including the EMBARK study and the long-term follow-up cohorts. We do not put numbers in marketing form on this page because the right honest comparison for your family is your son's current North Star Ambulatory Assessment score against the patient subgroups in the published data, not an averaged headline number.
The workup that decides eligibility
Before any of the rest of the pathway opens, three results need to land.
First, genetic confirmation of a DMD-causing mutation. If your son has already been genetically tested, your neurologist will pull the report; if not, this is the first appointment. Whole-gene sequencing or MLPA-confirmed mutation detection is the standard. The pathology must be consistent with the FDA-approved label.
Second, anti-AAVrh74 antibody serology. A meaningful fraction of children have pre-existing antibodies to the AAVrh74 viral vector from prior environmental exposure. A positive titre is a contraindication. The test is run by reference laboratories and typically returns in 7 to 10 days. SKMC and SSMC in Abu Dhabi, and American Hospital Dubai for cases coordinated through Dubai, have run this workup on UAE soil for several DMD families.
Third, baseline hepatic and cardiac function. The new boxed warning makes this non-negotiable. Active hepatitis, elevated transaminases, prior liver injury, and concurrent hepatotoxic medications all need to be assessed and, where present, addressed before the infusion is scheduled. Cardiac MRI baseline is also part of most centres' protocols even though DMD cardiomyopathy presents later in the disease course.
A clinical rationale letter from your neurologist will document all three findings, the North Star score and other functional baselines, the rehabilitation plan, and the requested treatment.
The UAE regulatory pathway: how it actually works in 2026
The Emirates Drug Establishment, which absorbed 44 of the Ministry of Health and Prevention's regulatory functions by early 2026, is now the federal authority you and your treating hospital file through. The named-patient mechanism, which Elevidys uses because the product is not on the standard UAE registration list, is filed via ede.gov.ae by the hospital's import pharmacy on the treating neurologist's behalf. The Department of Health Abu Dhabi or Dubai Health Authority adds the emirate-level layer depending on where the infusion is given.
The UAE has done this before with confidence. On 19 March 2024, Sheikh Khalifa Medical City in Abu Dhabi administered gene transfer therapy to the emirate's first DMD patient, working under the Department of Health Abu Dhabi's coordination. SKMC's paediatric neurology unit, led by Dr Omar Ismayl, is the most documented UAE infrastructure for this specific therapy in this specific patient population. Sheikh Shakhbout Medical City in Abu Dhabi has also delivered cell- and gene-based therapies including exon-skipping products and is staffed by paediatric neurologists with rare-disease experience. American Hospital Dubai's paediatric neurology, under Dr Ubaid Shah, and Mediclinic City Hospital's paediatric neurology unit are Dubai-side options when emirate of residence and DHA coordination are the preferred route.
If you are not in Abu Dhabi or Dubai, our coordination still routes the infusion through one of these qualified centres, with travel scoped into the case management.
In our experience, EDE coordination on a complete, well-documented gene-therapy case runs three to six weeks from filing to approval. Complex cases, particularly any case with hepatic complexity or antibody-borderline serology, can extend longer.
The cost conversation, in the form a UAE family needs
The Elevidys drug price in 2026 sits in an indicative range of roughly USD 3.0 to 3.5 million, or approximately AED 11 to 13 million, for the one-time infusion product itself. That is the manufacturer's price for the gene therapy. The full cost of care includes the pre-infusion workup we described above, the infusion-day admission, the peri-infusion immunomodulation protocol (oral corticosteroids beginning approximately one day before the infusion and tapering over weeks), the intensive monitoring schedule for the first six months, and any travel costs if the qualified centre is not in your emirate.
When we issue a quote at intake, we separate every line: drug, qualified-centre admission, immunomodulation drugs, monitoring labs, our coordination fee. Nothing is bundled. We do not put a markup on the manufacturer's drug price. We do charge a transparent coordination fee for the case-management work, which is disclosed in writing before any funds move.
Insurance coverage of Elevidys in the UAE is uneven. Daman has reimbursed cases through prior-authorisation pathways for certain employer plans; private insurers vary widely. We supply your insurer with the documentation packet at no charge. We do not process the claim or guarantee coverage. Most UAE Elevidys cases to date have proceeded as cash-pay with partial post-treatment reimbursement.
The six months after the infusion
The peri-infusion immunomodulation protocol is intensive. Your son will be on oral corticosteroids in addition to his existing DMD steroid regimen for roughly the first eight weeks. Weekly liver function panels (AST, ALT, GGT, bilirubin) for the first three months and biweekly through month six are the published monitoring standard. Cardiac surveillance for myocarditis includes troponin checks and echocardiography per the centre's protocol. Hospitalisation for steroid-responsive hepatitis is uncommon but not rare; admission for acute liver injury, which is what the boxed warning addresses, is the safety event that the monitoring schedule is designed to catch early.
A practical implication for the family: your son's school attendance, sports participation, and social activity will be partially restricted for several weeks while the immune response is being managed. We coordinate with the family on this side of the case too, including communication with the school and arranging for any tutoring or remote-learning support if you ask.
What Reserve Meds does, and what we do not do
Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. For a UAE family pursuing Elevidys, our scope is the regulatory documentation packet, the EDE filing in collaboration with your treating hospital's import pharmacy, the sourcing logistics from the manufacturer's authorised US distribution through DSCSA-compliant chain of custody, cold-chain shipment to the qualified UAE centre, and named case-lead coordination from intake to the six-month post-infusion follow-up.
Reserve Meds is not your son's prescriber. We do not practise medicine. We do not manufacture Elevidys. We do not own or operate the infusion centre. We are not your insurer. Clinical decisions stay with your paediatric neurologist and the qualified centre; we are the operational layer that turns those decisions into a coordinated case.
We work cash-pay. Our coordination fee is disclosed in writing. We will not start work without a signed engagement.
A note for families weighing this
For Muslim families thinking through the religious-ethical dimension, the Islamic-bioethics consensus on disease-modifying therapies that preserve life and function is broadly permissive, and the families we have coordinated for have routinely consulted with their religious advisors before committing. We will not pressure that conversation. We have found that the families who proceed have usually taken between two and six weeks from first call to engagement, with most of that time used for extended-family consultation, financial preparation, and religious counsel. The clinical window means we ask families to be honest with themselves about the timeline. We do not push.
What to do if you want to start
The first concrete step is a call with our case-lead so we can confirm whether Elevidys is the right consideration for your son before any documentation work begins. Most families reach us first on WhatsApp, which is the medium we hold open during UAE business hours and on weekends for active cases.
Start your son's case on the portal, or open a WhatsApp conversation with the case-lead and we will take it from there.
Composite case examples; no individual patient is depicted. This content is for general information and does not constitute medical advice. Reserve Meds is a US-based concierge coordinator; we are not the prescriber and not the dispensing pharmacy. Clinical decisions remain with your treating paediatric neurologist.
Clinical and regulatory review: Mohammad Ali, MD (US-trained physician, Chief AI Officer, Reserve Meds). Last medically reviewed: 2026-05-20.
Regulatory status of Elevidys in United Arab Emirates, 2026
Elevidys (delandistrogene moxeparvovec-rokl) is not currently held on the locally registered medicines list of the Ministry of Health and Prevention (MOHAP). The product is approved by the US Food and Drug Administration per the labelled indication of ambulatory and non-ambulatory patients aged 4 years and older with Duchenne muscular dystrophy with a confirmed mutation in the DMD gene (see the FDA label at accessdata.fda.gov). The European Medicines Agency holds a parallel marketing authorisation where applicable (see the EMA EPAR at ema.europa.eu).
Because Elevidys is not on the MOHAP locally registered list, access for a United Arab Emirates-based patient runs through the named-patient and personal-import framework that the MOHAP maintains for reference-authority-approved medicines that are not held locally. The official MOHAP portal is at mohap.gov.ae. The qualifying conditions are well established: the medicine is approved by a recognised reference authority (FDA or EMA qualifies); no locally available alternative is clinically equivalent for the specific patient indication; the treating physician of record takes documented clinical responsibility; and chain of custody is preserved end to end from the US source through international transit to the named dispensing facility.
The named-patient and personal-import pathway is the routine framework. For a complex cell or gene therapy that requires a US-certified treatment center, the practical route is patient travel to that certified center rather than import into United Arab Emirates; see Block 2 below for the operational shape on that case type.
Tertiary centers and clinical coordination in United Arab Emirates
The United Arab Emirates tertiary referral network for a Elevidys case is concentrated at Cleveland Clinic Abu Dhabi (CCAD), Sheikh Shakhbout Medical City (SSMC), and Tawam Hospital. These centers carry the haematology, oncology, paediatric subspecialty, or rare-disease specialist staffing and the institutional pharmacy and import-license operations that the named-patient pathway requires. For cellular and gene therapies that require leukapheresis collection, AAV infusion, or post-treatment monitoring of a complexity beyond what a community centre is configured for, the case is routinely referred to one of these tertiary centers from the outset.
For cell and gene therapies specifically, the practical access pathway runs through patient travel to a US-certified treatment center (Casgevy authorised treatment centers, Yescarta certified centers, Abecma certified centers, Zolgensma certified centers, Elevidys treatment centers, Hemgenix treatment centers, and so on) rather than import of the cellular or AAV product into United Arab Emirates. The tertiary United Arab Emirates centers handle the upstream referral package assembly (clinical summary, pathology, imaging, organ function panel, infectious disease screen, performance status), the US-side coordination, and the long-term follow-up after the patient returns home. Reserve Meds coordinates the cross-border arc between the United Arab Emirates tertiary team and the US treatment center, including travel and accommodation logistics, financial clearance, and post-treatment data flow.
For oral kinase inhibitors and antibody therapies that can be administered in United Arab Emirates once imported, the tertiary centres dispense and monitor under their institutional pharmacy operations. Reserve Meds handles US-side sourcing under Drug Supply Chain Security Act (DSCSA) chain-of-custody documentation, international shipment to the named dispensing facility, and re-supply cadence aligned to the dosing schedule.
United Arab Emirates pricing reference and payer posture, 2026
Reserve Meds publishes a drug-only US cash-pay reference range at intake and issues a delivered, itemised quote within 24 hours once your treating physician's documentation is in. As an illustrative composite case in the 2026 reference band, the US cash-pay drug-only range for Elevidys sits at approximately USD 3,200,000 to USD 3,300,000 per one-time AAV gene therapy infusion (US wholesale acquisition cost). In AED terms at the 2026 reference rate of 1 USD = 3.670 AED, that translates to a drug-only band of approximately AED 11,744,000 to AED 12,111,000.
Logistics, international shipment, chain-of-custody documentation, cold-chain handling where applicable, US treatment center facility and physician fees where applicable (for cellular and gene therapies, the facility cost commonly equals or exceeds the product cost), Reserve Meds concierge coordination, and any patient and caregiver travel and accommodation are itemised separately. For a cell or gene therapy case the total course cost in 2026 commonly lands at 1.5x to 2.5x the drug-only band once US treatment center fees, lymphodepletion or pre-infusion conditioning, inpatient monitoring, complication management, and family travel and accommodation are added in.
Payer posture in United Arab Emirates is overwhelmingly cash-pay for named-patient imports and cross-border CAR-T cases. Public coverage (DHA Dubai Health Authority and DoH Abu Dhabi insurance schemes) generally does not extend to non-locally-registered specialty cases. Private health insurance plans review case-by-case on a pre-authorisation basis when the documentation package is strong, but cash-pay should be assumed as the default at intake.
Access barriers and how Reserve Meds clears them
The five access barriers we see most often for a Elevidys case in United Arab Emirates are: (1) Regulatory documentation complexity. The MOHAP named-patient and personal-import application package requires a specific bundle (physician clinical rationale letter, prescription, patient identifier, product strength and quantity, chain-of-custody plan, evidence of reference-authority approval, and confirmation that no locally available alternative is clinically equivalent for the patient). Reserve Meds provides physician-facing templates that match the format MOHAP reviewers expect. (2) US-side sourcing and DSCSA chain-of-custody. We coordinate with our US-licensed specialty wholesale partners to secure Elevidys from authorised distribution under the US Drug Supply Chain Security Act, logging every transfer point through to international shipment.
(3) For cell and gene therapies, the US-certified treatment center qualification gate. Casgevy, Yescarta, Carvykti, Abecma, Zolgensma, Elevidys, Hemgenix, and Luxturna can only be administered at a manufacturer-certified treatment center. Reserve Meds maintains the referral arcs to the appropriate US-certified centers and handles the referral package routing, financial clearance, and the multi-week stay coordination. (4) Family logistics. Patient and caregiver travel, accommodation near the treatment center, in-US transport, translator support where needed, and post-treatment data flow back to the treating United Arab Emirates physician are coordinated as a single arc. (5) Insurance and payer posture. Cash-pay is the default. Where private insurance review is contemplated, we supply documentation for the family's submission but we do not bill insurers and we do not adjudicate insurance disputes.
Drug-specific clinical context for Elevidys: the labelled indication is ambulatory and non-ambulatory patients aged 4 years and older with Duchenne muscular dystrophy with a confirmed mutation in the DMD gene. The relevant clinical-practice guideline body is Parent Project Muscular Dystrophy clinical care guidelines at www.parentprojectmd.org. Your treating physician of record makes the clinical decision; Reserve Meds is the coordination layer that clears the operational and regulatory barriers between the prescription and the delivered course.
Recent regulatory and access news for Elevidys in United Arab Emirates, 2026
The Ministry of Health and Prevention (MOHAP) portal at mohap.gov.ae has not posted a Elevidys-specific listing on the publicly searchable locally registered medicines list at mohap.gov.ae/en/services/medicine-search as of 2026-06-04. The FDA Drug Safety Communications feed at fda.gov drug-safety-communications and the FDA Drug Shortages list at accessdata.fda.gov drugshortages have not registered a Elevidys-specific safety advisory or shortage signal over the most recent 12-month window. The FDA labelled indication remains ambulatory and non-ambulatory patients aged 4 years and older with Duchenne muscular dystrophy with a confirmed mutation in the DMD gene (see the current label at accessdata.fda.gov). Sarepta Therapeutics continues commercial supply per the FDA-labelled indication and the EMA marketing authorisation. The Parent Project Muscular Dystrophy clinical care guidelines guidance at www.parentprojectmd.org remains the relevant clinical-practice reference. Reserve Meds refreshes this snapshot per case at intake; the snapshot date governs.